Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA

doi:10.3748/wjg.v10.i3.427

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5270)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

511

HTML

4498

Figures (1-2)

130

Tables (1-4)

131

Sum=5270

Feb 1, 2004 (publication date) through Apr 22, 2024

Times Cited of This Article

Times Cited (113)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Feb 1, 2004; 10(3): 427-432
Published online Feb 1, 2004. doi: 10.3748/wjg.v10.i3.427

Full Size Figure Download Figure

Figure 1 Mean serum CA19-9 and CEA concentrations. ^aP < 0.001, ^bP < 0.05 vs benign biliary diseases or healthy individuals. ^cP < 0.05 vs serum CEA.

Citation: Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA. World J Gastroenterol 2004; 10(3): 427-432
URL: https://www.wjgnet.com/1007-9327/full/v10/i3/427.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i3.427